Literature DB >> 15120473

On estimators of medical costs with censored data.

Anthony O'Hagan1, John W Stevens.   

Abstract

In the assessment of cost-effectiveness of alternative medical technologies, it is necessary to estimate the mean total cost per patient over the relevant patient population. Where information about costs comes from a clinical trial with censored data, care is needed to estimate mean total costs. We examine the theoretical connections between the two most widely used of a growing range of nonparametric estimators of costs under censoring. By clarifying the relationships between these simple methods we hope to make them more accessible and to facilitate the take-up of more sophisticated techniques. Recommendations are offered regarding the most appropriate of the available methods, but also on the potential for greater efficiency through parametric modelling. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Year:  2004        PMID: 15120473     DOI: 10.1016/j.jhealeco.2003.06.006

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  14 in total

1.  Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

Authors:  V F Fragoulakis; A G Pallis; D K Kaitelidou; N M Maniadakis; V G Georgoulias
Journal:  Lung Cancer (Auckl)       Date:  2012-07-16

2.  Nonparametric inference for median costs with censored data.

Authors:  Hongwei Zhao; Chen Zuo; Shuai Chen; Heejung Bang
Journal:  Biometrics       Date:  2012-02-24       Impact factor: 2.571

3.  Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs.

Authors:  Shuai Chen; Hongwei Zhao
Journal:  Biostatistics       Date:  2013-02-19       Impact factor: 5.899

4.  Semiparametric Estimation of Longitudinal Medical Cost Trajectory.

Authors:  Liang Li; Chih-Hsien Wu; Jing Ning; Xuelin Huang; Ya-Chen Tina Shih; Yu Shen
Journal:  J Am Stat Assoc       Date:  2018-06-18       Impact factor: 5.033

5.  Some insight on censored cost estimators.

Authors:  H Zhao; Y Cheng; H Bang
Journal:  Stat Med       Date:  2011-07-11       Impact factor: 2.373

6.  Estimating mean total costs in the presence of censoring: a comparative assessment of methods.

Authors:  Tracey A Young
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Long-term health care costs for prostate cancer patients on androgen deprivation therapy.

Authors:  M D Krahn; K E Bremner; J Luo; G Tomlinson; S M H Alibhai
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

8.  Average cost-effectiveness ratio with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

9.  Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation.

Authors:  Bernadette Li; John Cairns; James Fotheringham; Rommel Ravanan
Journal:  Eur J Health Econ       Date:  2015-07-08

10.  Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Authors:  Robert I Griffiths; Michelle L Gleeson; Joseph Mikhael; Mark D Danese
Journal:  J Cancer Epidemiol       Date:  2012-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.